| Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity CIM Dahlberg, D Sarhan, M Chrobok, AD Duru, E Alici Frontiers in immunology 6, 605, 2015 | 233 | 2015 |
| Triticum durum metallothionein: isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling K Bilecen, UH Ozturk, AD Duru, T Sutlu, MV Petoukhov, DI Svergun, ... Journal of Biological Chemistry 280 (14), 13701-13711, 2005 | 86 | 2005 |
| The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment K Uttervall, AD Duru, J Lund, J Liwing, G Gahrton, E Holmberg, J Aschan, ... PLoS One 9 (7), e101819, 2014 | 74 | 2014 |
| Natural killer cells in clinical development as non-engineered, engineered, and combination therapies N Lamers-Kok, D Panella, AM Georgoudaki, H Liu, D Özkazanc, ... Journal of Hematology & Oncology 15 (1), 164, 2022 | 60 | 2022 |
| Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D EC Sayitoglu, AM Georgoudaki, M Chrobok, D Ozkazanc, BJ Josey, M Arif, ... Frontiers in immunology 11, 40, 2020 | 52 | 2020 |
| Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ... Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019 | 44 | 2019 |
| Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ... European journal of immunology 49 (8), 1278-1290, 2019 | 41 | 2019 |
| Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice P Brodin, T Lakshmikanth, R Mehr, MH Johansson, AD Duru, A Achour, ... PLoS One 5 (10), e13174, 2010 | 32 | 2010 |
| Lipid-based transfection reagents exhibit cryo-induced increase in transfection efficiency H Sork, JZ Nordin, JJ Turunen, OPB Wiklander, B Bestas, EM Zaghloul, ... Molecular Therapy-Nucleic Acids 5, 2016 | 30 | 2016 |
| Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets E Kavak, A Najafov, N Ozturk, T Seker, K Cavusoglu, T Aslan, AD Duru, ... Cellular signalling 22 (10), 1523-1535, 2010 | 25 | 2010 |
| Functional assessment for clinical use of serum-free adapted NK-92 cells M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ... Cancers 11 (1), 69, 2019 | 24 | 2019 |
| Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. E Alici, M Chrobok, J Lund, T Ahmadi, I Khan, AD Duru, H Nahi British journal of haematology 174 (3), 2016 | 21 | 2016 |
| Deletion of chromosomal region 8p21 confers resistance to bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma AD Duru, T Sutlu, A Wallblom, K Uttervall, J Lund, B Stellan, G Gahrton, ... PLoS One 10 (9), e0138248, 2015 | 21 | 2015 |
| Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex C Madhurantakam, AD Duru, T Sandalova, JR Webb, A Achour PLoS One 7 (3), e32805, 2012 | 20 | 2012 |
| Retracted Paper-Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome P Jungebluth, B Holzgraefe, ML Lim, AD Duru, V Lundin, N Heldring, ... Respiration 90 (6), 481-492, 2015 | 16 | 2015 |
| Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells F Rossi, B Josey, EC Sayitoglu, R Potens, T Sultu, AD Duru, V Beljanski PLoS One 15 (9), e0239238, 2020 | 15 | 2020 |
| The MHC class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer I Hafstrand, EM Doorduijn, AD Duru, J Buratto, CC Oliveira, T Sandalova, ... The Journal of Immunology 196 (5), 2327-2334, 2016 | 14 | 2016 |
| Unexpected T‐cell recognition of an altered peptide ligand is driven by reversed thermodynamics EB Allerbring, AD Duru, H Uchtenhagen, C Madhurantakam, MB Tomek, ... European journal of immunology 42 (11), 2990-3000, 2012 | 12 | 2012 |
| ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma N Mensali, H Köksal, S Joaquina, P Wernhoff, NP Casey, P Romecin, ... Nature Communications 14 (1), 3375, 2023 | 11 | 2023 |
| The immunogenicity of a proline-substituted altered peptide ligand toward the cancer-associated TEIPP neoepitope Trh4 is unrelated to complex stability I Hafstrand, EM Doorduijn, R Sun, A Talyzina, M Sluijter, S Pellegrino, ... The Journal of Immunology 200 (8), 2860-2868, 2018 | 9 | 2018 |
Adnane AchourProfessor in Molecular Immunology在 ki.se 的电子邮件经过验证
